Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijantimicag.2020.106114 http://scihub22266oqcxt.onion/10.1016/j.ijantimicag.2020.106114 32712334!7377772!32712334     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Antimicrob+Agents 2020 ; 56 (3): 106114 Nephropedia Template TP {{tp|p=32712334|t=2020. Ribavirin therapy for severe COVID-19: a retrospective cohort study |pdf=|usr=}}{{32712334}} gab.com Text Ribavirin therapy for severe COVID-19: a retrospective cohort study JO: Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32712334 #FOAvip The aim of this study was to compare ribavirin therapy versus supportive therapy only for patients with severe coronavirus disease 2019 (COVID-19). A total of 115 patients with laboratory-confirmed COVID-19 were retrospectively analysed. All patients received supportive care as well as regular laboratory and clinical monitoring. The 115 patients comprised 44 patients who received intravenous ribavirin (treatment group) and 71 who did not (control group). Baseline laboratory and clinical characteristics were similar between the two groups. The negative conversion time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR in the ribavirin group was 12.8 +/- 4.1 days compared with 14.1 +/- 3.5 days in the control group (P = 0.314). Moreover, 7/41 patients (17.1%) in the ribavirin group died compared with 17/69 (24.6%) in the control group (P = 0.475). Adverse effects were similar between the two groups. In conclusion, in patients with severe COVID-19, ribavirin therapy is not associated with improved negative conversion time for SARS-CoV-2 test and is not associated with an improved mortality rate. Further assessment in designed randomised controlled trials is recommended. Twit Text FOAVip Ribavirin therapy for severe COVID-19: a retrospective cohort study ????Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32712334 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32712334 #FOAvip English Wikipedia <ref>{{Cite pmid|32712334}}</ref> Ribavirin therapy for severe COVID-19: a retrospective cohort study #MMPMID32712334 Tong S; Su Y; Yu Y; Wu C; Chen J; Wang S; Jiang J Int J Antimicrob Agents 2020[Sep]; 56 (3): 106114 PMID32712334show ga The aim of this study was to compare ribavirin therapy versus supportive therapy only for patients with severe coronavirus disease 2019 (COVID-19). A total of 115 patients with laboratory-confirmed COVID-19 were retrospectively analysed. All patients received supportive care as well as regular laboratory and clinical monitoring. The 115 patients comprised 44 patients who received intravenous ribavirin (treatment group) and 71 who did not (control group). Baseline laboratory and clinical characteristics were similar between the two groups. The negative conversion time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR in the ribavirin group was 12.8 +/- 4.1 days compared with 14.1 +/- 3.5 days in the control group (P = 0.314). Moreover, 7/41 patients (17.1%) in the ribavirin group died compared with 17/69 (24.6%) in the control group (P = 0.475). Adverse effects were similar between the two groups. In conclusion, in patients with severe COVID-19, ribavirin therapy is not associated with improved negative conversion time for SARS-CoV-2 test and is not associated with an improved mortality rate. Further assessment in designed randomised controlled trials is recommended. |Adrenal Cortex Hormones/therapeutic use[MESH] |Aged[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects/immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/mortality/virology[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulins/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Patient Discharge[MESH] |Pneumonia, Viral/*drug therapy/mortality/virology[MESH] |Retrospective Studies[MESH] |Ribavirin/*therapeutic use[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH] |Time Factors[MESH]Ribavirin therapy for severe COVID-19: a retrospective cohort study (epmc).pdf DeepDyve Pubget Overpricing